JPMorgan Chase & Co. Raises Solid Biosciences (NASDAQ:SLDB) Price Target to $12.00

Solid Biosciences (NASDAQ:SLDB) had its target price raised by JPMorgan Chase & Co. from $11.00 to $12.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 67.36% from the stock’s current price.

Other research analysts also recently issued research reports about the stock. Wedbush reiterated an “outperform” rating and set a $14.00 price target on shares of Solid Biosciences in a research report on Wednesday, March 11th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Solid Biosciences in a report on Monday. Citigroup reiterated a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of Solid Biosciences in a research note on Friday, March 20th. Finally, Chardan Capital restated a “buy” rating and issued a $15.00 price target on shares of Solid Biosciences in a report on Friday, March 20th. Eleven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Solid Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $16.09.

Solid Biosciences Stock Up 7.3%

Shares of SLDB stock traded up $0.49 during mid-day trading on Wednesday, reaching $7.17. The stock had a trading volume of 177,305 shares, compared to its average volume of 1,352,834. The firm’s 50 day simple moving average is $6.50 and its 200 day simple moving average is $5.81. The firm has a market cap of $558.61 million, a PE ratio of -3.57 and a beta of 2.65. Solid Biosciences has a one year low of $2.41 and a one year high of $8.72.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.01. Sell-side analysts forecast that Solid Biosciences will post -2.84 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Jessie Hanrahan sold 26,535 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $6.44, for a total value of $170,885.40. Following the completion of the transaction, the insider owned 82,675 shares of the company’s stock, valued at $532,427. This represents a 24.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO David T. Howton sold 37,771 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $6.44, for a total value of $243,245.24. Following the completion of the sale, the chief operating officer owned 116,753 shares in the company, valued at $751,889.32. This trade represents a 24.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 597,672 shares of company stock valued at $3,816,546. Corporate insiders own 13.63% of the company’s stock.

Institutional Trading of Solid Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in SLDB. Legal & General Group Plc increased its stake in shares of Solid Biosciences by 208.6% in the second quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after buying an additional 4,063 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Solid Biosciences by 205.5% during the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after acquiring an additional 4,534 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Solid Biosciences by 142.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock valued at $63,000 after acquiring an additional 5,991 shares during the last quarter. Creative Planning bought a new position in Solid Biosciences in the second quarter valued at about $57,000. Finally, Police & Firemen s Retirement System of New Jersey raised its holdings in Solid Biosciences by 233.8% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock worth $74,000 after purchasing an additional 10,585 shares during the period. 81.46% of the stock is currently owned by institutional investors.

Key Stories Impacting Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: HC Wainwright raised its quarterly and full‑year EPS forecasts for 2026 (Q1–Q4) and lifted FY2026 loss estimates to (‑$1.43) from (‑$2.12), while keeping a “Buy” rating and a $20 price target — a more constructive analyst outlook helped support the rally. Article Title
• Positive Sentiment: HC Wainwright’s model also projects eventual profitability in later years (FY2029: $0.89 EPS; FY2030: $1.81 EPS), signaling a pathway to long‑term upside if the company executes on clinical and commercial milestones. Article Title
• Neutral Sentiment: The market consensus still shows significant near‑term losses (current consensus FY running ~‑$2.84 EPS). HC Wainwright’s improved forecasts are meaningful relative to prior estimates but do not remove near‑term loss risk.
• Neutral Sentiment: Multiple short‑interest updates published for March show “0 shares” and NaN changes — data appears inconsistent or misreported, so there’s no clear signal of increased short pressure from those reports.
• Negative Sentiment: Despite analyst optimism, Solid remains unprofitable through HC Wainwright’s 2026–2027 forecasts (multiple quarters of negative EPS). Execution, clinical progress, and cash runway remain primary downside risks for the stock if milestones slip.

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.